Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 164 of the 165 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to update the guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONCLUSIONS: We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the American Association of Clinical Endocrinologists187, the Endocrine Society425 and the Obesity Society186 have not recommended testosterone supplementation as a treatment for sarcopenia or obesity.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [425]
In the citing paper
“In line with this data, the Endocrine Society Guidelines (62) and the Third International Consultation on Sexual Medicine (63) emphasized that lifestyle modifications should be strongly encouraged in hypogonadal subjects with obesity, T2DM, and the MetS.”
From Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis (2013) · cites this paper as [62]
In the citing paper
“T levels demonstrate an age-related decline (96,97).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [97]
In the citing paper
“Current Endocrine Society guidelines recommend measuring fT in men with low-normal TT levels in whom SHBG alterations are suspected with low values established within each laboratory.”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [1]
In the citing paper
“Similarly, guidelines by the Endocrine Society have agreed upon a lower TT threshold for therapeutic consideration at 280–300 ng/dl (9.7–10.4 nmol/L).”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [1]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force elected to use the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) work group, an international group with expertise in development and implementation of evidencebased guidelines (1).”
MethodA Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“Free testosterone level can be measured accurately by equilibrium dialysis or calculated from total testosterone, SHBG, and albumin (20).”
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 3×
“The average decline in serum testosterone levels with aging in men is 1–2% per year (7, 8).”
BackgroundThompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 1×
“The average decline in serum testosterone levels with aging in men is 1–2% per year (7, 8).”
BackgroundSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846 · cited 1×
“1 Non-placebo-controlled studies Lowering of testosterone concentrations in adult men by surgical orchiectomy or by GnRH agonist or antagonist administration is associated with rapid and marked loss of bone mineral density (29), increase in fat mass (45), and a TABLE 3.”
BackgroundThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 1×
“5 mg/d of prednisone or its equivalent increases the risk of gonadotropin and testosterone suppression and alterations in muscle and bone mass (149).”
BackgroundRosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 3×
“Most of the circulating testosterone is bound to SHBG and to albumin (18, 19); only 0.”
BackgroundMethodThe Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Self-citationBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 2×
“diabetes, and comorbidities or health status (9, 12, 13).”
BackgroundAssessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938 · cited 1×
“testosterone treatment (76), but it can only be used for men”
MethodKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“Some studies have demonstrated favorable effects in men with obesity (65, 66) or type 2 diabetes (67), and in healthy older men (68).”
BackgroundLoss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men*
Bremner, W. J., Vitiello, M. V., & Prinz, P. N. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1278 · Cited by 785 · cited 1×
“Serum testosterone levels exhibit a circadian variation with peak values in the morning; this circadian rhythm is blunted with aging (16).”
BackgroundEffects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768 · cited 1×
“However, several randomized trials have found no significant effects of testosterone therapy on depression in older men with low or low-normal testosterone levels (127, 133).”
BackgroundPrevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Self-citationPrevalence of Symptomatic Androgen Deficiency in Men
Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., Clark, R. V., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1245 · Cited by 720
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Self-citationValidation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662 · cited 1×
“There is limited information about the performance properties of case-detection instruments that rely on selfreport, namely, Androgen Deficiency in Aging Males (41), the Aging Males’ Symptoms Rating Scale (42), and the Massachusetts Male Aging Study Questionnaire (43).”
BackgroundWang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Self-citationFrequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Testosterone influences spatial cognition in older men.
Janowsky, J. S., Oviatt, S. K., & Orwoll, E. S. (1994) · Behavioral Neuroscience · doi:10.1037//0735-7044.108.2.325 · Cited by 579 · cited 1×
“The effects of testosterone on cognitive function are poorly understood; some studies report small effects on visuospatial cognition and verbal memory and fluency (63, 64).”
BackgroundEffects of Testosterone Replacement in Hypogonadal Men1
Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6731 · Cited by 572 · cited 1×
“Testosterone therapy of healthy, hypogonadal men also increases fat-free mass (47, 48, 54– 57) and muscle strength (47, 54) and decreases fat mass (47, 48, 57).”
BackgroundSelf-citationDHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Self-citationLong-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559
The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.
Mårin, P., Holmäng, S., Jönsson, L., Sjöström, L., Kvist, H., Holm, G., Lindstedt, G., & Björntorp, P. A. (1992) · PubMed · Cited by 553
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552 · cited 1×
“symptoms below this threshold than above it (11, 15).”
BackgroundBhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544 · cited 1×
“Testosterone administration in hypogonadal men is associated with a dose-dependent increase in hemoglobin levels (109–111); the increase in hemoglobin is greater in older men than in young hypogonadal men (110, 111).”
BackgroundSelf-citationEffect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · cited 2×
“Quality of life Four placebo-controlled randomized trials reported on testosterone’s effect on quality of life (119, 129, 133, 134).”
BackgroundResultSelf-citationTestosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men1
Bhasin, S., Storer, T. W., Berman, N., Yarasheski, K. E., Clevenger, B., Phillips, J., Lee, W. P., Bunnell, T. J., & Casaburi, R. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3733 · Cited by 522 · cited 1×
“Testosterone therapy of healthy, hypogonadal men also increases fat-free mass (47, 48, 54– 57) and muscle strength (47, 54) and decreases fat mass (47, 48, 57).”
BackgroundSelf-citationFerrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., Achacosa, A., Lieberman, S. A., Tipton, K., Wolfe, R. R., & Urban, R. J. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00362.2001 · Cited by 522
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Low Serum Testosterone and Mortality in Male Veterans
Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1660 · Cited by 487
Self-citationAmory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · cited 1×
“A systematic review of randomized, placebo-controlled trials of 1- to 3-yr duration that evaluated effects on bone mineral density and were published before March 2005 yielded inconsistent and imprecise results (118, 120, 122, 132); these trials showed a moderate treatment effect on lumbar bone mineral density (0.”
ResultSelf-citationEffect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460 · cited 1×
“A systematic review of randomized, placebo-controlled trials of 1- to 3-yr duration that evaluated effects on bone mineral density and were published before March 2005 yielded inconsistent and imprecise results (118, 120, 122, 132); these trials showed a moderate treatment effect on lumbar bone mineral density (0.”
ResultSelf-citationKenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456 · cited 1×
“A systematic review of randomized, placebo-controlled trials of 1- to 3-yr duration that evaluated effects on bone mineral density and were published before March 2005 yielded inconsistent and imprecise results (118, 120, 122, 132); these trials showed a moderate treatment effect on lumbar bone mineral density (0.”
ResultBlackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study
Wang, C. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3578 · Cited by 453 · cited 1×
“Testosterone therapy improves the positive and reduces the negative aspects of mood (60, 61).”
BackgroundSelf-citationTestosterone supplementation improves spatial and verbal memory in healthy older men
Cherrier, M. M., Asthana, S., Plymate, S., Baker, L., Matsumoto, A. M., Peskind, E., Raskind, M. A., Brodkin, K., Bremner, W., Petrova, A., et al. (2001) · Neurology · doi:10.1212/wnl.57.1.80 · Cited by 451 · cited 1×
“The effects of testosterone on cognitive function are poorly understood; some studies report small effects on visuospatial cognition and verbal memory and fluency (63, 64).”
BackgroundSelf-citationBrodsky, I. G., Balagopal, P., & Nair, K. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855787 · Cited by 444
Steidle, C., Schwartz, S., Jacoby, K., Sebree, T., Smith, T., & Bachand, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021058 · Cited by 411
Travison, T. G., Araujo, A. B., Kupelian, V., O’Donnell, A. B., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1859 · Cited by 410 · cited 1×
“diabetes, and comorbidities or health status (9, 12, 13).”
BackgroundSHABSIGH, R., KAUFMAN, J. M., STEIDLE, C., & PADMA-NATHAN, H. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132389.97804.d7 · Cited by 406
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1692 · Cited by 404 · cited 1×
“Testosterone administration in hypogonadal men is associated with a dose-dependent increase in hemoglobin levels (109–111); the increase in hemoglobin is greater in older men than in young hypogonadal men (110, 111).”
BackgroundSelf-citationTestosterone and Depression: Systematic Review and Meta-Analysis
Zarrouf, F. A., Artz, S., Griffith, J., Sirbu, C., & Kommor, M. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358315.88931.fc · Cited by 383 · cited 1×
“A recent systematic review of randomized trials reported significantly greater improvements in depression scores in testosterone-treated men than in placebo-treated men (135).”
BackgroundDobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381
Bhasin, S. (2000) · JAMA · doi:10.1001/jama.283.6.763 · Cited by 369
Self-citationMauras, N., Hayes, V., Welch, S., Rini, A., Helgeson, K., Dokler, M., Veldhuis, J. D., & Urban, R. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4892 · Cited by 368
Zmuda, J. M., Cauley, J. A., Kriska, A., Glynn, N. W., Gutai, J. P., & Kuller, L. H. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009326 · Cited by 368
Testosterone Therapy in Glucocorticoid-Treated Men
Reid, I. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440100065008 · Cited by 365
Wang, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2839 · Cited by 359 · cited 1×
“Testosterone therapy of healthy, hypogonadal men also increases fat-free mass (47, 48, 54– 57) and muscle strength (47, 54) and decreases fat mass (47, 48, 57).”
BackgroundSelf-citationWittert, G. A., Chapman, I. M., Haren, M. T., Mackintosh, S., Coates, P., & Morley, J. E. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.7.m618 · Cited by 345
Aversa, A., Isidori, A. M., Spera, G., Lenzi, A., & Fabbri, A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01764.x · Cited by 343
KWAN, M., GREENLEAF, W. J., MANN, J., CRAPO, L., & DAVIDSON, J. M. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-557 · Cited by 339
SKAKKEBAEK, N. E., BANCROFT, J., DAVIDSON, D. W., & WARNER, P. (1981) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1981.tb00364.x · Cited by 336
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Haddad, R. M., Kennedy, C. C., Caples, S. M., Tracz, M. J., Boloña, E. R., Sideras, K., Uraga, M. V., Erwin, P. J., & Montori, V. M. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.1.29 · Cited by 331 · cited 2×
“(3) of studies found through October 2004 enrolling older men with low testosterone levels yielded insignificant changes in major lipid fractions [total cholesterol standardized mean difference (SMD), 0.”
BackgroundSelf-citationSecondary Hypogonadism in Older Men: Its Relation to Impotence*
KORENMAN, S. G., MORLEY, J. E., MOORADIAN, A. D., DAVIS, S. S., KAISER, F. E., SILVER, A. J., VIOSCA, S. P., & GARZA, D. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-963 · Cited by 320 · cited 1×
“may coexist in middle-aged and older men (53, 84).”
BackgroundSexual dysfunction in men and women with endocrine disorders
Bhasin, S., Enzlin, P., Coviello, A., & Basson, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60280-3 · Cited by 319 · cited 1×
“may coexist in middle-aged and older men (53, 84).”
BackgroundSelf-citationBhasin, S., Calof, O. M., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V. M., Gao, W., & Dalton, J. T. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0120 · Cited by 300 · cited 2×
“Body weight and LBM In a systematic review of randomized, placebo-controlled trials of testosterone therapy in HIV-infected patients with weight loss that reported body composition (125), 3 to 6 months of testosterone therapy was associated with greater gains in body weight ( 1.”
BackgroundSelf-citationChanges in erectile responsiveness during androgen replacement therapy
Bancroft, J., & Wu, F. C. W. (1983) · Archives of Sexual Behavior · doi:10.1007/bf01542116 · Cited by 288
Tracz, M. J., Sideras, K., Boloña, E. R., Haddad, R. M., Kennedy, C. C., Uraga, M. V., Caples, S. M., Erwin, P. J., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0036 · Cited by 275 · cited 1×
“A systematic review of randomized, placebo-controlled trials of 1- to 3-yr duration that evaluated effects on bone mineral density and were published before March 2005 yielded inconsistent and imprecise results (118, 120, 122, 132); these trials showed a moderate treatment effect on lumbar bone mineral density (0.”
ResultSelf-citationThe Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men
Liu, P. Y., Yee, B., Wishart, S. M., Jimenez, M., Jung, D. G., Grunstein, R. R., & Handelsman, D. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030236 · Cited by 275
Blood Testosterone Threshold for Androgen Deficiency Symptoms
Kelleher, S., Conway, A. J., & Handelsman, D. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0143 · Cited by 274 · cited 1×
“symptoms below this threshold than above it (11, 15).”
BackgroundSex Steroids and All-Cause and Cause-Specific Mortality in Men
Araujo, A. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1252 · Cited by 272
Buchter, D., Behre, H., Kliesch, S., & Nieschlag, E. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390298 · Cited by 269
The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone
Fowler, J. E., & Whitmore, W. F. (1981) · Journal of Urology · doi:10.1016/s0022-5347(17)54531-0 · Cited by 261 · cited 1×
“Metastatic prostate cancer and breast cancer are hormone-dependent cancers that may be stimulated to grow during testosterone treatment (71); testosterone should not be administered to men with these cancers.”
BackgroundBuvat, J., & Lemaire, A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64123-5 · Cited by 247
Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men
Tivesten, A., Vandenput, L., Labrie, F., Karlsson, M. K., Ljunggren, O., Mellström, D., & Ohlsson, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2650 · Cited by 243
Grinspoon, S. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4051 · Cited by 243
Stimulation of Spermatogenesis by Gonadotropins in Men with Hypogonadotropic Hypogonadism
Finkel, D. M., Phillips, J. L., & Snyder, P. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509123131102 · Cited by 240
Self-citationCrawford, B. A. L., Liu, P. Y., Kean, M. T., Bleasel, J. F., & Handelsman, D. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021827 · Cited by 237 · cited 1×
“In two placebo-controlled trials (150, 151), testosterone therapy of men receiving glucocorticoid treatment for bronchial asthma or chronic obstructive pulmonary disease was associated with a greater gain in LBM (2.”
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236 · cited 1×
“The suppression of testosterone is particularly profound in men on methadone maintenance therapy because of its long duration of action; buprenorphine suppresses plasma testosterone to a lesser extent than methadone (24).”
BackgroundTestosterone and Aging: Clinical Research Directions
(2004) · National Academies Press eBooks · doi:10.17226/10852 · Cited by 231
Richie, J. P., Catalona, W. J., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1993) · Urology · doi:10.1016/0090-4295(93)90359-i · Cited by 230
ANDROGEN REPLACEMENT AFTER CURATIVE RADICAL PROSTATECTOMY FOR PROSTATE CANCER IN HYPOGONADAL MEN
KAUFMAN, J. M., & GRAYDON, R. J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000136269.10161.32 · Cited by 229
Singh, A. B. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.136 · Cited by 226
Self-citationBhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., & Cunningham, G. R. (2003) · Journal of Andrology · doi:10.1002/j.1939-4640.2003.tb02676.x · Cited by 221 · cited 1×
“6 ng/ml shouldbe followedusinga standardized,monitoring plan (Table 8) to facilitate early detection of adverse events and to prevent unnecessary prostate biopsies that might lead to detectionofsubclinicalprostatecancer(77,98).”
BackgroundSelf-citationRabkin, J. G., Wagner, G. J., & Rabkin, R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.141 · Cited by 213
Grinspoon, S., Corcoran, C., Parlman, K., Costello, M., Rosenthal, D., Anderson, E., Stanley, T., Schoenfeld, D., Burrows, B., Hayden, D., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-5-200009050-00010 · Cited by 208
Brambilla, D. J., O'Donnell, A. B., Matsumoto, A. M., & McKinlay, J. B. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02976.x · Cited by 207 · cited 3×
“In a community-based, multiethnic cohort of middle-aged to older men, day-to-day variations in serum testosterone concentrations were found to be sufficiently large that single testosterone measurements were inadequate to characterize an individual’s levels, and at least two testosterone measurements were needed to di…”
BackgroundInfluentialSelf-citationTESTOSTERONE REPLACEMENT THERAPY AFTER PRIMARY TREATMENT FOR PROSTATE CANCER
AGARWAL, P. K., & OEFELEIN, M. G. (2005) · Journal of Urology · doi:10.1097/01.ju.0000143942.55896.64 · Cited by 206
Smith, K. W., Feldman, H. A., & McKinlay, J. B. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01152.x · Cited by 203 · cited 1×
“There is limited information about the performance properties of case-detection instruments that rely on selfreport, namely, Androgen Deficiency in Aging Males (41), the Aging Males’ Symptoms Rating Scale (42), and the Massachusetts Male Aging Study Questionnaire (43).”
BackgroundTESTOSTERONE SUPPLEMENTATION FOR ERECTILE DYSFUNCTION: RESULTS OF A META-ANALYSIS
JAIN, P., RADEMAKER, A. W., & MCVARY, K. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67363-6 · Cited by 202 · cited 1×
“lished studies (85), 57% of subjects experienced an im-”
BackgroundBenign and Malignant Neoplasms of the Prostate
Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36262-6 · Cited by 197
Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., Reback, E., Porter, V., Swerdloff, R., & Cummings, J. L. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.nct50002 · Cited by 197 · cited 1×
“Cognition Three placebo-controlled, randomized trials (130, 133, 136), one of which studied patients with Alzheimer’s dementia and low testosterone levels (136), reported imprecise effects on several dimensions of cognition, none of which was significant after pooling.”
BackgroundSelf-citationAndrogen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues.
Mårin, P., Krotkiewski, M., & Björntorp, P. A. (1992) · PubMed · Cited by 192
Sarosdy, M. F. (2007) · Cancer · doi:10.1002/cncr.22438 · Cited by 190
Testosterone Therapy for Low Sexual Interest and Erectile Dysfunction in Men: a Controlled Study
O'Carroll, R., & Bancroft, J. (1984) · British Journal of Psychiatry · doi:10.1192/bjp.145.2.146 · Cited by 188
Boloña, E. R., Uraga, M. V., Haddad, R. M., Tracz, M. J., Sideras, K., Kennedy, C. C., Caples, S. M., Erwin, P. J., & Montori, V. M. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60963-4 · Cited by 184 · cited 4×
“25), and no significant effect on overall sexual satisfaction (4).”
BackgroundInfluentialSelf-citationKenny, A. M., Bellantonio, S., Gruman, C. A., Acosta, R. D., & Prestwood, K. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m321 · Cited by 177 · cited 3×
“Cognition Three placebo-controlled, randomized trials (130, 133, 136), one of which studied patients with Alzheimer’s dementia and low testosterone levels (136), reported imprecise effects on several dimensions of cognition, none of which was significant after pooling.”
BackgroundPredictive accuracy and sources of variability in calculated free testosterone estimates
Sartorius, G., Ly, L. P., Sikaris, K., McLachlan, R., & Handelsman, D. J. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2008.008171 · Cited by 175
Kalinchenko, S. Y., Kozlov, G. I., Gontcharov, N. P., & Katsiya, G. V. (2003) · The Aging Male · doi:10.1080/tam.6.2.94.99 · Cited by 173
Rietschel, P., Corcoran, C., Stanley, T., Basgoz, N., Klibanski, A., & Grinspoon, S. (2000) · Clinical Infectious Diseases · doi:10.1086/317457 · Cited by 171
Comparison of screening questionnaires for the diagnosis of hypogonadism
Morley, J. E., Perry, H. M., Kevorkian, R. T., & Patrick, P. (2006) · Maturitas · doi:10.1016/j.maturitas.2005.07.004 · Cited by 168
Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample
Hall, S. A., Esche, G. R., Araujo, A. B., Travison, T. G., Clark, R. V., Williams, R. E., & McKinlay, J. B. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0021 · Cited by 167 · cited 2×
“but was unrelated to race and ethnicity (12).”
BackgroundOxandrolone in AIDS-wasting myopathy
Berger, J. R., Pall, L., Hall, C. D., Simpson, D. M., Berry, P. S., & Dudley, R. (1996) · AIDS · doi:10.1097/00002030-199612000-00010 · Cited by 166
The influence of aging on plasma sex hormones in men: the Telecom study.
Simon, D., Preziosi, P., Barrett-Connor, E., Roger, M., Saint-Paul, M., Nahoul, K., & Papoz, L. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116365 · Cited by 166
Mohr, B. A., Bhasin, S., Link, C. L., O’Donnell, A. B., & McKinlay, J. B. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02241 · Cited by 163
Self-citationTestosterone Replacement Therapy Following Radical Prostatectomy
Khera, M., Grober, E. D., Najari, B., Colen, J. S., Mohamed, O., Lamb, D. J., & Lipshultz, L. I. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01161.x · Cited by 162
Kenny, A. M., Fabregas, G., Song, C., Biskup, B., & Bellantonio, S. (2004) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/59.1.m75 · Cited by 161 · cited 1×
“Cognition Three placebo-controlled, randomized trials (130, 133, 136), one of which studied patients with Alzheimer’s dementia and low testosterone levels (136), reported imprecise effects on several dimensions of cognition, none of which was significant after pooling.”
BackgroundBhasin, S., Storer, T. W., Asbel-Sethi, N., Kilbourne, A., Hays, R., Sinha-Hikim, I., Shen, R., Arver, S., & Beall, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5079 · Cited by 159
Self-citationDifferential Anabolic Effects of Testosterone and Amino Acid Feeding in Older Men
Ferrando, A. A., Sheffield-Moore, M., Paddon-Jones, D., Wolfe, R. R., & Urban, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021041 · Cited by 156
The Aging Males’ Symptoms Scale (AMS) as Outcome Measure for Treatment of Androgen Deficiency
Moore, C., Huebler, D., Zimmermann, T. P., Heinemann, L. A. J., Saad, F., & Thai, D. M. (2004) · European Urology · doi:10.1016/j.eururo.2004.01.009 · Cited by 149 · cited 1×
“There is limited information about the performance properties of case-detection instruments that rely on selfreport, namely, Androgen Deficiency in Aging Males (41), the Aging Males’ Symptoms Rating Scale (42), and the Massachusetts Male Aging Study Questionnaire (43).”
BackgroundTHE EPIDEMIOLOGY OF PLASMA TESTOSTERONE LEVELS IN MIDDLE-AGED MEN
DAI, W. S., KULLER, L. H., LAPORTE, R. E., GUTAI, J. P., FALVO-GERARD, L., & CAGGIULA, A. (1981) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113251 · Cited by 148
Plasma testosterone concentrations in asthmatic men treated with glucocorticoids.
Reid, I. R., Ibbertson, H. K., France, J. T., & Pybus, J. (1985) · BMJ · doi:10.1136/bmj.291.6495.574 · Cited by 145
Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men
CUNNINGHAM, G. R., HIRSHKOWITZ, M., KORENMAN, S. G., & KARACAN, I. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-792 · Cited by 139
Self-citationEffects of Hypogonadism and Testosterone Administration on Depression Indices in HIV-Infected Men1
Grinspoon, S., Corcoran, C., Stanley, T., Baaj, A., Basgoz, N., & Klibanski, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6224 · Cited by 138
Testosterone Supplementation in Older Men: A Rational Idea Whose Time Has Not Yet Come
BHASIN, S., & BUCKWALTER, J. G. (2001) · Journal of Andrology · doi:10.1002/j.1939-4640.2001.tb02570.x · Cited by 135 · cited 2×
“The benefits and adverse consequences of longterm testosterone therapy on patient-important outcomes in asymptomatic men with presumed hypogonadism remain unclear (35, 36).”
BackgroundSelf-citationOpen-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135 · cited 1×
“In a small open-label trial, testosterone therapy has been reported to improve some quality-of-life measures such as sexual function, well-being, and mood in men with opioid-induced androgen deficiency (22).”
BackgroundLow bone density in patients receiving methadone maintenance treatment
Kim, T. W., Alford, D. P., Malabanan, A., Holick, M. F., & Samet, J. H. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.05.027 · Cited by 131
LIU, L., BANKS, S. M., BARNES, K. M., & SHERINS, R. J. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-6-1140 · Cited by 131
Effect of Testosterone Administration on Sexual Behavior and Mood in Men with Erectile Dysfunction
Schiavi, R. C., White, D., Mandeli, J., & Levine, A. C. (1997) · Archives of Sexual Behavior · doi:10.1023/a:1024518730222 · Cited by 121
Basaria, S. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.005454 · Cited by 119 · cited 1×
“Androgen deprivation therapy using GnRH analogs in men with prostate cancer has emerged as an important cause of therapeutically induced androgen deficiency that is associated with increased risk of sexual dysfunction, fatigue, fractures, cardiovascular disease, and diabetes (25).”
BackgroundCavallini, G., Caracciolo, S., Vitali, G., Modenini, F., & Biagiotti, G. (2004) · Urology · doi:10.1016/j.urology.2003.11.009 · Cited by 118 · cited 1×
“two parallel trials (48, 82) and three crossover trials (49,”
BackgroundGREENSTEIN, A., MABJEESH, N. J., SOFER, M., KAVER, I., MATZKIN, H., & CHEN, J. (2005) · Journal of Urology · doi:10.1097/01.ju.0000149870.36577.05 · Cited by 116
Carani, C., Granata, A. R. M., Bancroft, J., & Marrama, P. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00017-8 · Cited by 113
Seftel, A. D., Mack, R. J., Secrest, A. R., & Smith, T. M. (2004) · Journal of Andrology · doi:10.1002/j.1939-4640.2004.tb03169.x · Cited by 108
Testosterone replacement therapy in HIV illness
Rabkin, J. G., Rabkin, R., & Wagner, G. (1995) · General Hospital Psychiatry · doi:10.1016/0163-8343(94)00062-i · Cited by 100 · cited 1×
“Uncontrolled studies report improvements in energy and sense of well-being after testosterone therapy (62).”
BackgroundSerum hormones in men with human immunodeficiency virus-associated wasting
Dobs, A. S. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4108 · Cited by 95 · cited 1×
“B Evidence There is a high prevalence of low testosterone levels in HIV-infected men (37, 38, 137): 20–25% of HIV-infected men on highly active antiretroviral therapy have low testosterone levels (137).”
BackgroundTestosterone Versus Fluoxetine for Depression and Fatigue in HIV/AIDS: A Placebo-Controlled Trial
Rabkin, J. G., Wagner, G. J., McElhiney, M. C., Rabkin, R., & Lin, S. H. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132442.35478.3c · Cited by 95
Carani, C., Bancroft, J., Granata, A., Del Rio, G., & Marrama, P. (1992) · Psychoneuroendocrinology · doi:10.1016/0306-4530(92)90023-z · Cited by 95
Basu, R., Man, C. D., Campioni, M., Basu, A., Nair, K. S., Jensen, M. D., Khosla, S., Klee, G., Toffolo, G., Cobelli, C., et al. (2007) · Diabetes Care · doi:10.2337/dc07-0359 · Cited by 91
Citron, J. T., Ettinger, B., Rubinoff, H., Ettinger, V. M., Minkoff, J., Hom, F., Kan, P., & Alloo, R. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)66441-3 · Cited by 89
DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters
Rabkin, J. G., Ferrando, S. J., Wagner, G. J., & Rabkin, R. (2000) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00036-0 · Cited by 88
Analysis of variation in prostate-specific antigen values
Riehmann, M., Rhodes, P. R., Cook, T. D., Grose, G. S., & Bruskewitz, R. C. (1993) · Urology · doi:10.1016/0090-4295(93)90364-g · Cited by 87
Testosterone Therapy For Human Immunodeficiency Virus-Positive Men With and Without Hypogonadism
Rabkin, J. G., Wagner, G. J., & Rabkin, R. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00006 · Cited by 87
Orengo, C. A., Fullerton, L., & Kunik, M. E. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704271767 · Cited by 79
Bhasin, S., Zhang, A., Coviello, A., Jasuja, R., Ulloor, J., Singh, R., Vesper, H., & Vasan, R. S. (2008) · Steroids · doi:10.1016/j.steroids.2008.07.003 · Cited by 79 · cited 2×
“Most of the circulating testosterone is bound to SHBG and to albumin (18, 19); only 0.”
BackgroundSelf-citationMatsumoto, A. M., Snyder, P. J., Bhasin, S., Martin, K. A., Weber, T. J., Winters, S. J., Spratt, D. I., Brentzel, J., & O'Dea, L. S. L. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.07.1742 · Cited by 77
Self-citationAn integrative review on current evidence of testosterone replacement therapy for the andropause
Tan, R. S., & Culberson, J. W. (2003) · Maturitas · doi:10.1016/s0378-5122(03)00083-5 · Cited by 72
Wang, C., Iranmanesh, A., Berman, N., McDonald, V., Steiner, B., Ziel, F., Faulkner, S. M., Dudley, R. E., Veldhuis, J. D., & Swerdloff, R. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.4996 · Cited by 72
Self-citationTestosterone therapy in HIV wasting syndrome: systematic review and meta-analysis
Kong, A. H., & Edmonds, P. M. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00441-3 · Cited by 71
CARANI, C. (1990) · Hormones and Behavior · doi:10.1016/0018-506x(90)90020-x · Cited by 70
Shamloul, R., Ghanem, H., Fahmy, I., El-Meleigy, A., Ashoor, S., Elnashaar, A., & Kamel, I. (2005) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2005.00071.x · Cited by 69
Aminorroaya, A., Kelleher, S., Conway, A. J., Ly, L. P., & Handelsman, D. J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01920 · Cited by 68 · cited 1×
“Testosterone therapy improves the positive and reduces the negative aspects of mood (60, 61).”
BackgroundAllan, C. A., Forbes, E. A., Strauss, B. J., & McLachlan, R. I. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.22 · Cited by 65
Harman, S. M., & Blackman, M. R. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071236 · Cited by 62
Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone
Hwang, T.-S., Chen, H.-E., Tsai, T.-F., & Lin, Y. C. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901446 · Cited by 61
The effect of testosterone on health-related quality of life in elderly males - a pilot study
Reddy, P., White, C. M., Dunn, A. B., Moyna, N. M., & Thompson, P. D. (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00309.x · Cited by 57 · cited 1×
“Quality of life Four placebo-controlled randomized trials reported on testosterone’s effect on quality of life (119, 129, 133, 134).”
BackgroundARVER, S., SINHA‐HIKIM, I., BEALL, G., GUERRERO, M., SHEN, R., & BHASIN, S. (1999) · Journal of Andrology · doi:10.1002/j.1939-4640.1999.tb02562.x · Cited by 56 · cited 1×
“B Evidence There is a high prevalence of low testosterone levels in HIV-infected men (37, 38, 137): 20–25% of HIV-infected men on highly active antiretroviral therapy have low testosterone levels (137).”
BackgroundSelf-citationKnapp, P. E., Storer, T. W., Herbst, K. L., Singh, A. B., Dzekov, C., Dzekov, J., LaValley, M., Zhang, A., Ulloor, J., & Bhasin, S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90213.2008 · Cited by 56
Self-citationAlexander, G. M., & Sherwin, B. B. (1991) · Hormones and Behavior · doi:10.1016/0018-506x(91)90008-6 · Cited by 53
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · Cited by 45
Self-citationClopper, R. R., Voorhess, M. L., MacGillivray, M., Lee, P. A., & Mills, B. (1993) · Psychoneuroendocrinology · doi:10.1016/0306-4530(93)90066-t · Cited by 44
Prostate-Specific Antigen and Digital Rectal Examination in Screening for Prostate Cancer
Bretton, P. R. (1994) · Southern Medical Journal · doi:10.1097/00007611-199407000-00009 · Cited by 42
Salehian, B., Jacobson, D. L., Swerdloff, R. S., Grafe, M. R., Sinha‐Hikim, I., & McCutchan, J. A. (1999) · Endocrine Practice · doi:10.4158/ep.5.1.1 · Cited by 40 · cited 2×
“Low testosterone levels are associ- ated with weight loss, progression to AIDS (138), wasting (139), depression, and loss of muscle mass and exercise capacity (139).”
BackgroundSelf-citationGosselaar, C., Roobol, M. J., Roemeling, S., de Vries, S. H., van der Cruijsen‐Koeter, I., van der Kwast, T., & Schröder, F. H. (2005) · The Prostate · doi:10.1002/pros.20359 · Cited by 35
Serum PSA and Percent Free PSA Value Changes after Antibiotic Treatment
Kobayashi, M., Nukui, A., & Morita, T. (2008) · Urologia Internationalis · doi:10.1159/000112612 · Cited by 34 · cited 1×
“If prostatitis is suspected, appropriate antibiotic treatment has been reported to decrease PSA by approximately 30% (100, 101).”
BackgroundThe responsible use of antibiotics for an elevated PSA level
Scardino, P. T. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0702 · Cited by 30 · cited 1×
“If prostatitis is suspected, appropriate antibiotic treatment has been reported to decrease PSA by approximately 30% (100, 101).”
BackgroundKlinefelter’s Syndrome—A Microcosm of Male Reproductive Health
Handelsman, D. J., & Liu, P. Y. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0156 · Cited by 23
HORMONES AND HUMAN SEXUAL BEHAVIOUR
Bancroft, J. (1981) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071693 · Cited by 21
Screening for carcinoma of the prostate with prostate specific antigen.
Muschenheim, F., Omarbasha, B., Kardjian, P., & Mondou, E. (1991) · PubMed · Cited by 20
Serum Testosterone Levels During Chronic Glucocorticoid Therapy
Reid, I. R. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-639 · Cited by 14 · cited 1×
“B Evidence Testosterone levels are lower in glucocorticoid-treated men than in age-matched controls (39).”
BackgroundPSA variability versus velocity.
Carter, H. B. (1997) · PubMed · Cited by 11
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“The evidence for effects of testosterone replacement on outcomes is mixed, and recent guidelines suggest that screening and treatment of men without symptoms are not recommended (398).”
BackgroundStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Self-citation
Metadata
- Authors
- Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M.
- Affiliations
- Boston University (US)
- Baylor College of Medicine (US)
- University College Dublin (IE)
- University of Washington (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-06
- Volume
- 95
- Issue
- 6
- Pages
- 2536-2559
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2142563833
- Semantic Scholar
- df10a9d7e1ce096bd0507b8f7cbafe35494eee8c
- Cited by
- 1,954
- References
- 165
- Citations by year
- 2026: 23 · 2025: 50 · 2024: 68 · 2023: 66 · 2022: 75 · 2021: 71 · 2020: 85 · 2019: 105 · 2018: 159 · 2017: 211 · 2016: 190 · 2015: 186 · 2014: 228 · 2013: 162 · 2012: 139
- FWCI
- 103.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, hypogonadism, serum total testosterone, sex hormone-binding globulin, prostate-specific antigen, obstructive sleep apnea, heart failure, sexual function, bone mineral density, testosterone formulations, treatment monitoring
- MeSH terms
- Adult, Aged, Androgens, Humans, Hypogonadism, Male, Middle Aged, Monitoring, Physiologic, Sexual Dysfunction, Physiological, Syndrome, Testosterone, HIV Infections, Randomized Controlled Trials as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.